Viatris Inc (VTRS)

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026

Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 PR Newswire PITTSBURGH, July 1...

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy

Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary...

Form 8-K - Current report

Viatris figure parmi les Meilleurs lieux de travail(MC) au Canada en 2026

Viatris figure parmi les Meilleurs lieux de travail(MC) au Canada en 2026 Canada NewsWire ETOBICOKE...

Form 8-K - Current report

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of...

Form 8-K - Current report

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference PR Newswire PITTSBURGH, May...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Viatris Reports First-Quarter 2026 Financial Results

Viatris Reports First-Quarter 2026 Financial Results PR Newswire PITTSBURGH, May 7, 2026 Delivers Total...